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OBJECTIVES: Infliximab (I) 5mg/kg is effective to con-
trol refractory Crohn’s disease in 81% and to improve
fistulas in 68% of patients, thus greatly improving qual-
ity of life (QoL). The objective of this study was to calcu-
late the direct costs generated by I to achieve this im-
provement of QoL in patients responding to therapy.
METHODS: This mirror-image study was carried out in
35 patients, 19 with refractory disease and 16 with fistu-
las, responding to therapy. All patients were followed at
the same institution solely for at least six months prior
and six months after I. All direct costs to the Belgian pub-
lic payer were recorded for every 6-month time period
before and after I. The cost of I was calculated separately.
IBDQ scores were recorded before and after I for each
period. RESULTS: There was an important build up of
costs in each period (2 1.5y: 814 Euro; 1.5 1.0y:
1,408 Euro; 1.0 0.5: 2,250 Euro) culminating in a
cost of care of 2,456 Euro in the six months prior to I as
a result of the refractoriness of the disease. After I there
was a sharp decrease of the cost of care (excluding the
cost of I) to 2,024 Euro (0 0.5y) and 1,304 Euro (0.5
1.0y). The average cost of I in the first six months was
5,037 Euro and in the second six months 902 Euro. The
IBDQ increased from 147.8 (SE 8.4) to 187.8 (SE 7.0).
The total direct cost of care after I, adjusted for the re-
sponse rate, was calculated to be 16 Euro per day of nor-
malized QoL. CONCLUSIONS: Although the cost of in-
fliximab is substantial, the total direct cost to produce a
normal QoL in the entire year after therapy is quite ac-
ceptable, providing that patients not responding are not
further treated.
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CONTEXT: Victims due to the uneasiness, which is
caused by their socially shameful nature with persons
who suffer, haemorrhoids seem to be neglected by the
scientific community. There are lacks in the literature
concerning the health epidemiology and economy. Its
high prevalance and its invalidating aspect make that this
venous affection is a real health problem for public health
in the Western Countries: A prevalence of 4.4% is re-
ported. OBJECTIVE: Evaluating following a society per-
spective the cost of care for patients suffering from haem-
orrhoids. METHODOLOGY: Data presented come from
different bases (Medline, Pascal, Ohe-ifpma) as well as from
the SESI survey concerning pathologies treated in hospital
services for short duration as well as PMSI 2000. RESULTS:
American patients with mid or moderate haemorrhoids
have in average per year of: 1.25 medical consultations,
0.8 prescriptions and 1.38 medical/surgery procedures.
About 63.9% of patients are treated without drug. Sur-
gery seems to be done on 1.37% of the outpatients. 72%
of the financial cost of haemorrhoids seems to be due to
hospitalization for surgery. Following the SESI (last
available data, 1993), the number of estimated short hos-
pital stays for haemorrhoids is 51.400, which represents
0.4% of all annual French hospital short stays. 87.3% of
the stays are due to surgery. The average stay is 5.7 days;
the cost of stay can be estimated (data PMSI, 2000) to al-
most 1685 euros. CONCLUSION: The population suf-
fering from haemorrhoids is important and the financial
impact for the community is far from being negligible. By
extrapolation we have estimated the cost of care at 138
Millions Euros out of which 92 Millions of Euros are for
hospitalization only. This evaluation does not take into
consideration indirect cost or cost for self-medication.
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OBJECTIVE: With a prevalence up to 20%, IBS is one of
the most common diseases in the western world. IBS is
characterized by a combination of persistent and recur-
rent abdominal pain and abnormal bowel habits (diar-
rhea, constipation or both). IBS is said to be the second
most common cause of work absenteeism. Nevertheless,
the economic burden of IBS is often underestimated. This
study is the first one in Germany showing the burden of
mixed and constipation-type IBS. METHODS: The data
from 200 patient records were documented by physicians’
interviews. 100 patients were interviewed directly. Re-
source use in the past 12 months (physicians’ data) and 6
months (patients’ data) as well as quality of life data were
documented. RESULTS: The average annual societal
costs of IBS were DM 2,300 per patient. Of this, DM
1,729 was paid by the social sickness funds. Costs in-
creased with severity of disease, defined by subjects glo-
bal assessment (SGA), from DM 1,874 (mild) to DM
3,386 (severe/very severe) from the societal perspective
and from DM 1,552 to DM 2,703 from the health insur-
ance’s perspective. Cost drivers were drug expenditures
(33%), inability to work (21%) and outpatient treatment
